594865-28-8

Basic information

• Product Name: 1H-Pyrazolo[3,4-d]pyrimidin-4-amine, N-(3-fluorophenyl)-1-methyl-6-(methylthio)-
• CAS NO: 594865-28-8
• Molecular Formula: C13H12FN5S
• Molecular Weight: 289.336
• Mol File: 594865-28-8.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: 1H-Pyrazolo[3,4-d]pyrimidin-4-amine, N-(3-fluorophenyl)-1-methyl-6-(methylthio)-(CAS DataBase Reference)
• NIST Chemistry Reference: 1H-Pyrazolo[3,4-d]pyrimidin-4-amine, N-(3-fluorophenyl)-1-methyl-6-(methylthio)-(594865-28-8)
• EPA Substance Registry System: 1H-Pyrazolo[3,4-d]pyrimidin-4-amine, N-(3-fluorophenyl)-1-methyl-6-(methylthio)-(594865-28-8)

Safety Data

• Hazardous Substances Data: 594865-28-8(Hazardous Substances Data)

Upstream product

• 24521-76-4 4-hydroxy-6-mercapto-1H-pyrazolo[3,4-d]pyrimidine 
• 5334-26-9 4-hydroxy-6-methylmercapto-1H-pyrazolo[3,4-d]pyrimidine 
• 85426-79-5 4-chloro-6-methylmercapto-1H-pyrazolo[3,4-d]pyrimidine 
• 67-56-1 methanol 
• 594865-24-4 (3-fluoro-phenyl)-(6-methylsulfanyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-amine 

Downstream Products

• 594865-36-8 (3-fluoro-phenyl)-(6-methanesulfonyl-1-methyl-1H-pyrazolo[3,4-d]pyrimidin-4-yl)-amine 

Relevant articles and documents

Synthesis and biological evaluations of pyrazolo[3,4-d]pyrimidines as cyclin-dependent kinase 2 inhibitors

A series of 1,4,6-trisubstituted pyrazolo[3,4-d]pyrimidines 15-19, 30-38 capable of selectively inhibiting CDK2 activity were synthesized by derivatization at C-4, C-6 and N-1 with various amines and lower alkyl groups. For above synthetic compounds, biological evaluation was carried out and structure-activity relationship was examined. In our series, 4-anilino compounds exhibited better CDK2 inhibitory activity and antitumor activity compared to 4-benzyl compounds. The compounds 33a,b having a 3-fluoroaniline group at C-4 showed comparable or superior CDK2 inhibitory activity to those of olomoucine and roscovitine as reference compounds. In general, the unsubstituted compounds (30a,b, 33a,b, 36a,b) at N-1 possessed higher potency than the substituted compounds (32a,b, 34a,b) for the CDK2 inhibitory activity. As for EGFR inhibitory activity, most compounds didnot have a significant activity. The compounds 32a,b exhibited potent cell growth inhibitory activity against human cancer cell lines, but their CDK2 inhibitory activities were slightly poorer than olomoucine.